Diverse *cis* factors controlling *Alu* retrotransposition: What causes *Alu* elements to die?

Matthew S. Comeaux, Astrid M. Roy-Engel, Dale J. Hedges,¹ and Prescott L. Deininger²

Tulane Cancer Center and Dept. of Epidemiology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA

The human genome contains nearly 1.1 million *Alu* elements comprising roughly 11% of its total DNA content. *Alu* elements use a copy and paste retrotransposition mechanism that can result in de novo disease insertion alleles. There are nearly 900,000 old *Alu* elements from subfamilies S and J that appear to be almost completely inactive, and about 200,000 from subfamily Y or younger, which include a few thousand copies of the Ya5 subfamily which makes up the majority of current activity. Given the much higher copy number of the older *Alu* subfamilies, it is not known why all of the active *Alu* elements belong to the younger subfamilies. We present a systematic analysis evaluating the observed sequence variation in the different sections of an *Alu* element on retrotransposition. The length of the longest number of uninterrupted adenines in the A-tail, the degree of A-tail heterogeneity, the length of the 3' unique end after the A-tail and before the RNA polymerase III terminator, and random mutations found in the right monomer all modulate the retrotransposition efficiency. These changes occur over different evolutionary time frames. The combined impact of sequence changes in all of these regions explains why young *Alus* are currently causing disease through retrotransposition, and the old *Alus* have lost their ability to retrotranspose. We present a predictive model to evaluate the retrotransposition capability of individual *Alu* elements and successfully applied it to identify the first putative source element for a disease-causing *Alu* insertion in a patient with cystic fibrosis.

[Supplemental material is available online at www.genome.org.]

Alu elements have the highest copy number of all of the human mobile elements, contributing nearly 11% of the genome with about 1.1 million copies (Lander et al. 2001). *Alu* elements are nonautonomous; requiring protein products from L1 elements to carry out the generally accepted target primed reverse transcription (TPRT) process necessary for their amplification (Boeke 1997; Batzer and Deininger 2002; Kajikawa and Okada 2002; Dewannieux et al. 2003; Ostertag et al. 2003; Kazazian 2004). *Alu* can be subdivided into several different subfamilies based on their specific diagnostic sequence positions (for reviews, see Batzer et al. 1993; Batzer and Deininger 2002). *Alu* started to amplify about 65 million years ago, with peak amplification occurring around 40 million years ago, prior to the divergence of the old and new world monkeys (Shen et al. 1991; Lander et al. 2001; Batzer and Deininger 2002). Activity of the old *Alu*/S subfamilies declined while being replaced by the younger Y subfamily (~100,000 copies) (Shen et al. 1991). Subsets of the Y subfamilies are the only known *Alu* elements currently active in the human genome, with variants of the Y, Ya, and Yb lineages currently dominating activity (Deininger and Batzer 1999; Hedges et al. 2004; Mills et al. 2007; Belancio et al. 2008). There are ~900,000 older subfamily elements in the genome, predominately variants of the *Alu* S and J (Wang et al. 2006), and yet no de novo disease-associated insertions of these older elements have been found (Belancio et al. 2008).

Alu elements contribute significantly to human genetic instability; recent estimates calculate one new *Alu* insertion in every 20 live births (Cordaux et al. 2006), and at least one in every 1000

de novo genetic diseases are the result of an *Alu* insertion event (Deininger and Batzer 1999). There are at least 15 examples of Ya5 elements that have recently inserted causing disease (Belancio et al. 2008), despite there being only 3000 copies in the genome (Wang et al. 2006). In contrast, the older subfamilies have a 300-fold greater copy number than Ya5 while having no detectable amplification rate, suggesting that there must be at least a 4500-fold enrichment in activity per Ya5 copy relative to the old *Alu* subfamily members. This probably represents a minimal estimate as we have yet to see any *Alu*J or *Alu*Sx inserts generating disease alleles through insertional mutagenesis. To date, the exact reasons why these older *Alu* elements are “dead” or why only the younger *Alu* elements continue to amplify remain unclear. Surprisingly, *Alu* element insertions cause twice as much disease as L1 despite the fact that L1 is necessary for *Alu* activity (Belancio et al. 2008).

To further evaluate the reason older *Alu* elements are inactive, we looked at the different sequence components of an *Alu* element. Figure 1A shows a schematic of the basic structure of a transcript of a genomic *Alu* element. An *Alu* is a dimer of two nonidentical sequences ancestrally derived from the 7SL RNA gene separated by a middle A-rich region (Ullu and Tschudi 1984). The left monomer contains the internal RNA polymerase III (Pol III) promoter A and B boxes (Ullu and Tschudi 1984; Chu et al. 1995; Batzer and Deininger 2002). The basic *Alu* dimer is flanked by an adenosine (A) rich section (A-tail) at its 3' end. Because an *Alu* element does not encode its own Pol III terminator, *Alu* transcripts will contain a unique 3' end (Fig. 1A) derived from the genomic flanking region found between the end of the A-tail and the first downstream terminator sequence (usually –TTTT) present in the genomic flank. This sequence, which is effectively unique to each individual *Alu*, will be referred to as the 3' unique region. Because the A-tail of the transcript is used for the priming during retrotransposition, the 3' unique region associated with the parent (source) *Alu* is not included in the resulting insertion sequence.

¹Present address: Miami Institute for Human Genomics, 1120 NW 14th Street, Miami, FL 33136, USA.

²Corresponding author.

E-mail pdeinin@tulane.edu; fax (504) 988-5516.

Article published online before print. Article and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.089789.108>. Freely available online through the Genome Research Open Access option.

Figure 1. Schematic of *Alu* structure and transcript. (A) Representation of a typical transcript of a genomic *Alu* element with functional segments defined as the left and right monomers, A-tail, and 3' unique region. (B) Schematic of the *Alu* base construct used in this study with 7SL promoter-enhancer sequence upstream of the *Alu* and the necessary restriction enzymes used for construct manipulation. The neomycin selection cassette in reverse orientation with a self-splicing intron that allows for the retrotransposition studies is introduced after the *Alu* and before the A-tail. The selection cassette contains a Pol III terminator (TTTT) at the 3' end.

Therefore, it is not possible to unambiguously determine the 3' unique region of the source *Alu* from examining the genomic sequences of new insertions. Nevertheless, the individual characteristics of this sequence may be important to the "parent" *Alu*'s ability to retrotranspose.

Because *Alu* elements amplify through a Pol III-directed transcript, initial studies focused on transcription as a factor controlling the *Alu* activity. However, analysis of *Alu* transcripts recovered from cultured cells demonstrates that the majority of the transcripts (66%) were derived from the older *Alu* subfamilies (Sinnott et al. 1992; Maraia et al. 1993) and <1% derived from *AluYa5* elements (Shaikh et al. 1997), indicating that the RNA from older *Alu* elements was being made but was not undergoing retrotransposition. This expression of *Alu* subfamilies suggests that there is only about a sixfold difference in transcription per copy between older and younger *Alus* (Shaikh et al. 1997). Thus, transcriptional silencing does not appear to account for the lack of activity of the older *Alu* elements.

The younger, active subfamilies have a higher proportion of their members with long A-tails that then shrink rapidly in evolutionary terms (Roy-Engel et al. 2002; Odom et al. 2004). Although the bioinformatics made it seem possible that a primary factor differentiating older and younger *Alu* subfamilies was a threshold A-tail length (Roy-Engel et al. 2002), experimental studies with a tagged *Alu* in culture suggest that A-tail length only accounts for a modest difference in *Alu* activity between old and young subfamilies (Dewannieux and Heidmann 2005).

One possible explanation for subfamily differences in activity is that subfamily-specific sequence differences may result in altered interactions with the retrotransposition process (Sinnott et al. 1991). In addition, the older subfamily members have accumulated random mutations affecting the RNA secondary structures and/or the interactions with other components necessary for amplification (Sinnott et al. 1991; Alemán et al. 2000). For instance, mutations near the 5' end of the *Alu* sequence have been found to alter binding ability to SRP9/14 causing inactivation of the *Alu* activity (Sarrows et al. 1997; Bennett et al. 2008). In an effort to define *Alu* activity, Bennett and colleagues looked at the 280-bp "core" sequence of an *Alu* element (the left and right

monomers) and determined that mutations within the primary sequence play a role in *Alu* activity levels, but that many of the old *Alu* subfamily members would be expected to remain active (Bennett et al. 2008). Thus, none of the existing data fully explain the minimum 4500-fold effect needed to explain the inactivity of the older *Alu* subfamilies. It seems that other differences between the RNA molecules generated by the old versus young subfamilies must be major contributors to relative *Alu* activity (see Fig. 1A for *Alu* components). We included evaluations of random mutations usually present in older *Alus* that lead to an increased A-tail heterogeneity and microsatellite formation (Arcot et al. 1995). In addition, because each *Alu* transcript has a unique 3' end, this individual sequence may contribute major differences between individual elements contributing to the differences observed in *Alu* sub-

family activity. In this manuscript, we present systematic analyses evaluating the impact of the observed sequence variation in the different sections of an *Alu* element on retrotransposition. We describe both a model of the evolutionary kinetics of *Alu* inactivation and a predictive model of the rules of *Alu* retrotransposition capability by estimating the effect of the different *Alu* sequence components.

Results

A-tail length

A previous report demonstrated that the A-tail length influences the retrotransposition efficiency of a tagged *Alu* element (Fig. 1B) driven by a cotransfected full-length L1 element (Dewannieux and Heidmann 2005), but the level of variation observed would not provide much explanation of the differential efficiency of genomic Ya5 amplification relative to Sx elements. Our own studies confirm this observation when using either a cotransfected wild-type L1 (JM101/L1.3 no tag; Wei et al. 2001) or an ORF2-only expression plasmid to drive *Alu* retrotransposition (data not shown). However, we were concerned that the increased expression of L1 proteins in transient transfection experiments might lead to unusually high concentrations of ORF2p and artificially augment its interaction with shorter A-tail *Alus*. Thus, we transfected only the tagged *Alu* construct into HeLa cells, which express a detectable level of endogenous L1 (Belancio et al. 2006), to determine whether the A-tail lengths (Table 1) worked the same at these endogenous L1 expression conditions (Fig. 2). These studies confirmed the relative influence of the A-tail, with only a modest benefit accruing once the A-tail exceeded 20 bases (Dewannieux and Heidmann 2005).

A-tail heterogeneity

Because the older *Alu* elements also have less "perfect" A-tails than the newer elements, we hypothesized that disruption of the A-tails with other bases might serve the same role as shortening the A-tail. Figure 3 shows the distribution of uninterrupted A residues for a randomly chosen subset of *AluSx* ($n = 276$) and *AluYa5* ($n = 206$)

Construct	Sequence
Length	
A0	CTCTTTTGGCG
A10	CTCAAAAAAAAAATTTTGGCG
A20	CTCAAAAAAAAAAAAAAAAAAATTTTGGCG
A30	CTCAAAAAAAAAAAAAAAAAAAAAAAAAAATTTTGGCG
A40	CTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTTGGCG
A50	CTCAAATTTTGGCG
A80	CTCAAA AAAAAAATTTTGGCG
Heterogeneity	
A14T	CTCAAAAAAAAAAATAAAAAAAAAAATTTTGGCG
A9TA9G	CTCAAAAAAAAAATAAAAAAAAAAGAAAAAAAAAATTTTGGCG
A7TA7G	CTCAAAAAATAAAAAAGAAAAATAAAAAAATTTTGGCG
A5TA5G	CTCAAAATAAAAAAGAAAAATAAAAAGAAAAAATTTTGGCG
A3T	CTCAATAATAATAATAATAATAATAATAATAATTTTGGCG
A3C	CTCAACAACAACAACAACAACAACAACAATTTTGGCG
A3TA3C	CTCAATAAACAAATAAACAAATAAACAAATAATTTTGGCG
A3TC	CTCAATCAAAATCAAAATCAAAATCAAAATCAAAATCTTTTGGCG
A3TCTC	CTCAATCTCAAAATCTCAAAATCTCAAAATCTCAATTTTGGCG
A5C	CTCAAAACAAAAACAAAAACAAAAACAAAAACTTTTGGCG
A5G	CTCAAAAAGAAAAAGAAAAAGAAAAAGAAAAAGTTTTGGCG
A5TC	CTCAAAATCAAAATCAAAATCAAAATCAAAATCAATTTTGGCG
A5TCTC	CTCAAAATCTCAAAATCTCAAAATCTCAAAATCTCAATTTTGGCG
A14TCTCTC	CTCAAAAAAAAAAATCTCTCAAAAAAAAAATTTTGGCG
3' Flank	
A30-0	AAAAAAAAAAAAAAAAAAAAAAAAAATTTT
A30-15	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAATTCGCCCTTGAATTTT
A30-38	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAATTCAGAAAGGCCAAATAATCTACAAATCCTAACTTTT
A30-45	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAATTCGCCCTTATTCTAATACAAAGCAAAAGCATAAAGATCATTTTT
A30-70	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAATTCGCCCTTGAATTCTAGGTACATGCAATTTATTGGTAAAAATA GTGCCCTGTGCTATTTAATAATTTT
A30-126	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAATTCAGGGCGAATTCGCCCTTGAATTCTAAATAAAATCCCTT ATACAGAAAAAATAAAATAAAACTTGAGCAAGATCACACAGCAGGTATAAACAGCAGAGCTTCAAAACAGATTAGTTTTT

Genome Research 547
www.genome.org

Figure 3. Older *Alu* elements contain shorter homogenous A-stretches within the A-tail region than younger *Alus*. Data mining histogram that shows the frequency of *Alu* elements in different bin sizes (Sx $n = 276$; Ya5 $n = 206$)

or mutation of the L1.3 sequence that was cloned into an expression vector.

The distribution of altered bases relative to the length of uninterrupted As plays a role in *Alu* retrotransposition as both the A3TC and A14TCTCTCT constructs contain the same number of non-A bases but had significantly different capability driven under both conditions (Fig. 4B, $P < 0.02$ [endogenous], $P < 0.001$ [exogenous], paired Student's *t*-test). We observed a significant difference in activity of a 30-base A-tail disrupted with thymine residues when compared to a 30-base A-tail disrupted with cytosine residues in the exact same positions (Fig. 4B, $P < 0.02$ [endogenous], $P < 0.01$ [exogenous], Student's *t*-test), suggesting that the specific bases in the disruptions may also be important.

We further tested the relative influences of thymine (T), cytosine (C), and guanine (G) disruptions to the A-tail (Fig. 4C) and observed a general trend where $T \ll C < G$ when it comes to disruptions in the A-tail influencing *Alu* activity. The A3T construct retrotransposed much better than the A5C and A5G constructs even though it contains more disruptions ($P < 0.05$ and $P < 0.01$, respectively, Student's *t*-test), and the A5C construct showed more colony-forming ability than the A5G construct ($P < 0.01$, Student's *t*-test).

Analysis of the same randomly chosen Sx and Ya5 elements used for the A-tail length study (Supplemental Table 1S) demonstrated the existence of considerable differences between the degree and nature of disruptions in the A-tails of the elements from these two subfamilies (Table 2). A-tails from the *Alu*Sx elements have over eight times as many C and G disruptions as the Ya5 elements, suggesting that these elements should have diminished retrotransposition capability. Additionally, ~75% of the Ya5 elements have pure As in their tails, whereas only 21% of the Sx elements analyzed present no disruptions in their A-tails; 183 of the 276 Sx elements (66%) contain a C or G base, while only 32 of 206 (16%) of Ya5 A-tails contain either of these bases.

We were uncertain whether the A-tail disruptions contributed to changes in RNA stability or whether the disruptions were contributing at a later stage in the insertion process. Real-time reverse transcriptase PCR (qRT-PCR) was performed on the whole cell RNA extracts from cells transfected with the A30, A3T, A5C, and A5G constructs. Our results indicate that the observed retrotransposition differences could not be attributed to variations in the RNA steady-state levels, indicating that the RNA is present at similar levels (data not shown).

3' unique region

The most significant sequence difference between individual *Alu* transcripts is the downstream unique region located after the A-

tail and before the transcription terminator (Fig. 1A). Previous studies suggested that these sequences may modestly influence *Alu* RNA levels (Alemán et al. 2000). We generated several constructs that contain 3' unique regions of varying length ranging from 15 to 126 bp (Table 1). These sequences were selected as 3' flanking sequences of de novo L1 insertions from cell culture experiments (Gilbert et al. 2005). The selected sequences include the nucleotides immediately downstream from the A-tail to the first set of four T residues that would be expected to act as a Pol III terminator. We would expect these L1 flanking regions to be similar to *Alu* flanking regions (Jurka 1997) and they would have been unlikely to have undergone any negative selection. The constructs were compared to a 30-base pure A-tail (A30) immediately followed by a terminator (A30-0 from Table 1) to determine the effect of the differing 3' ends on *Alu* retrotransposition. The sequence found after the A-tail and prior to the terminator has a significantly detrimental effect on *Alu* retrotransposition rates whether under exogenous or endogenous conditions of ORF2p or L1 (Fig. 5A, $P < 0.01$ [exogenous], $P < 0.03$ [endogenous], Student's *t*-test). We see a strong decrease in *Alu* retrotransposition ability even with *Alus* containing little additional 3' end sequence.

Northern blot analyses demonstrate only modest transcription differences between the different 3' unique constructs and the A30-0 control (Fig. 5B). In this case, the observed transcription differences do not explain the huge decrease in activity, indicating that the observed effect of the 3' unique sequence on *Alu* retrotransposition capability is largely independent of RNA stability. Relative to the A30-0 construct, the A30-126 construct maintains only 13% and 7% effectiveness under exogenous and endogenous ORF2p conditions, respectively, but it has 67% of the level of the A30-0's RNA level.

We analyzed the 3' unique region (defined as the sequence between A-tail and the first four Ts in the 3' genomic flank) in a random sample of *Alu*Sx ($n = 289$) and Ya5 ($n = 227$) subfamilies and observed no significant difference in length distribution ($P = 0.69$, Student's *t*-test; Fig. 5C). However, only 25% of the Sx elements had 3' unique regions of 15 bases or less, indicating that close to 75% of these elements would be very limited in their retrotransposition capability, even if the other aspects of their 3' regions were ideal. Upon further examination, roughly 10% of the Sx elements contain sequence mutations that generate a Pol III terminator within their sequences leading to a truncated *Alu* transcript devoid of an A-tail and 3' unique sequence. When these premature terminating *Alus* are removed from the data set, only 17% of Sx elements present a 3' unique region <15 bp. We observe a similar distribution with the Ya5 elements, where only 15% of them contain 15 or fewer bases between the end of the A-tail and the genomic Pol III terminator. However, most of the 15% of Ya5 elements that do have a short 3' end would be expected to be active based on their A-tail homogeneity and length of continuous As.

Alu right monomer

Older *Alu* elements, such as Sx subfamily members, have accumulated more sporadic mutations throughout their length, which led to the proposal that this may disrupt structure or interactions relative to consensus elements (Sinnott et al. 1991; Alemán et al. 2000). Because the promoter resides in the left half of the element (Fig. 1A), we could not measure the influence of mutations in this region independently from transcription influences. Therefore, we selected different right halves from several randomly chosen *Alus*

Figure 4. Increased A-tail heterogeneity reduces *Alu* retrotransposition capability. HeLa cells were transiently transfected with the corresponding *Alu*-tagged constructs driven by endogenously or exogenously supplied ORF2p. The relative activity of *Alu* elements with slightly disrupted A-tails (A) or extremely disrupted A-tails (B) is shown. The *Alu* with 30 homogenous As (A30) was arbitrarily selected as 100%; the asterisk (*) indicates a significant difference from A30, $P < 0.05$ (Students paired *t*-test). (C) The evaluation of how specific base disruptions in the A-tail affect retrotransposition rate (T >> C > G) under exogenous conditions of ORF2p is shown. (*) Asterisk indicates a significant difference between A5C, A5G, and A3C relative to A3T, $P < 0.05$, $P < 0.01$, and $P < 0.01$, respectively (Students paired *t*-test); # indicates a significant difference between A5C and A5G, $P < 0.01$ (Students paired *t*-test).

to evaluate whether they influence the retrotransposition process. Nucleotide changes within the right monomer contribute sporadically to *Alu* activity (Fig. 6A; see Supplemental Table 2S for sequences). Some of the right monomer changes had no effect on *Alu* activity; however, others severely decreased *Alu* retrotransposition. These data demonstrate that a significant level of variation is likely to be tolerated, but certain mutations in the right monomer will affect retrotransposition, perhaps due to structural changes in the *Alu* RNA, which prevent its retrotransposition.

The steady-state RNA levels of these constructs were evaluated by Northern blot analysis (Fig. 6B). The difference in retrotransposition ability is not primarily due to RNA stability of these constructs. This indicates that something other than RNA level is the contributing factor to retrotransposition in these random right constructs and our observations are in good agreement with other recent results (Bennett et al. 2008) supporting RNA structure as an important factor in the retrotransposition mechanism.

Alu source element identification

A recent study (Chen et al. 2008) determined that an *Alu* insertion in the *Cftr* gene was a direct cause of cystic fibrosis. When we performed a genomic search with the sequence of the disease inserted *Alu*, only one *Alu* in the genome shared 100% identity (Fig. 7). This candidate source *Alu* shares a T mutation in the A-tail with the sequence of the disease causing *Alu*, a highly unusual feature in new *Alu* inserts. Although this first T residue in the A-tail is shifted slightly in one sequence relative to the other, we have found that this type of slippage in A-tail lengths is extremely common between A-tails in different individuals (Roy-Engel et al. 2002) and, therefore, this is likely to represent a shared T residue with an A length polymorphism. Our data suggest that the T mutation in the A-tail would not be expected to disrupt retrotransposition activity. In addition, this putative source *Alu* contains all of the features predicted by our data of an active *Alu*: a reasonable A-tail length with little disruption (34 bp) and a very short 3' unique region (0 bp) (Fig. 7). Collectively these observations, along with the data presented above, strongly suggest that we had identified the active "parent" or source *Alu* element responsible for the insertion into the *Cftr* gene. While it is impossible to demonstrate with absolute certainty, these observations likely represent the first identification of an active source *Alu* causing disease in humans,

and furthermore, they demonstrate how the rules defined in these studies assist us in understanding the retrotransposition potential of individual *Alu* elements.

Discussion

Our studies demonstrate why investigators have struggled for years to understand the pattern of evolutionary activity of *Alu* elements. The vast majority of *Alu* elements belong to older sub-families that have shown very little activity in recent evolutionary

Table 2. Analysis of nucleotide composition of the A-tail of young and old *Alu* elements

Subfamily	N	Percent of A ^a	Percent of T ^a	Percent of C ^a	Percent of G ^a	Percent of <i>Alu</i> with A only ^b	Percent of <i>Alu</i> with T ^c	Percent of <i>Alu</i> with C ^c	Percent of <i>Alu</i> with G ^c
Sx	276	84.49	6.77	4.57	4.16	21.38	42.39	36.59	44.93
Ya5	205	97.52	1.45	0.47	0.56	74.76	10.68	4.85	11.65

^aThe percentage of bases that make up the A-tails of the respective subfamilies.

^bThe percentage of elements in the respective subfamilies that have only As in their A-tails.

^cThe percentage of elements in each subfamily that have the listed base in their A-tail.

times. Instead, modern *Alu* activity is dominated by a few small, young *Alu* subfamilies (Deininger and Batzer 1999). The master-gene hypothesis (Deininger and Batzer 1995) was developed to explain subfamily evolution of rodent ID repeats whose evolution is clearly controlled by the BC1 master locus, and by analogy the model was extended to *Alu*. This model relied primarily on the transcriptional regulation of one, or a very few loci. At the time, we felt that the only other reasonable alternative is that, due to a very limited number of active *Alu* elements at any one time, their evolution goes through an extreme bottleneck, allowing the subfamilies to drift in the manner observed. In fact, the truth is probably a mix of these ideas, with the likelihood that a relatively few loci maintain activity for a longer period of time (master loci), while some loci have limited activity as proposed by the stealth model (Han et al. 2005), with the vast majority of *Alu* elements being retrotranspositionally incompetent.

Transcription is still likely to be a major factor limiting the activity of many *Alu* elements. They are heavily influenced by flanking sequences at each new insertion locus (Chesnokov and Schmid 1996; Alemán et al. 2000; Roy et al. 2000; Ludwig et al. 2005), silenced by methylation (Englander et al. 1993; Liu and Schmid 1993; Liu et al. 1994), and the older *Alus* gradually accumulate mutations that incapacitate the internal promoter (Murphy et al. 1983). Because our studies utilize an *Alu* whose transcription is assisted by the strong 7SL RNA gene upstream region, we cannot address the influence of genomic sequence on individual *Alu* loci. It is likely that the majority of *Alu* elements are in relatively poor transcriptional environments that limit their activity. However, every transcriptional study carried out on *Alu* elements (Sinnott et al. 1992; Liu et al. 1994; Shaikh et al. 1997) demonstrates that many *Alu* loci from all subfamilies continue to be transcriptionally active. Thus, the only way to explain the minimum of 4500-fold amplification preference of young *Alu* families, like Ya5, relative to the older *Alu* families is through post-transcriptional regulatory factors. It was previously proposed that A-tail length might be a major factor in this regulation (Roy-Engel et al. 2002). However, experimental studies demonstrated that only very short A-tails are retrotranspositionally inactive, and therefore old subfamilies have sufficient A-tail length that we estimate this influence should only be about threefold (Dewannieux and Heidmann 2005). It would be reasonable to expect that interruptions in the A-tail that gradually accumulate through mutation of older *Alu* elements would also influence the ability of an A-tail to successfully participate in the predicted TPRT priming (Boeke 1997). Our studies confirm the negative impact of some A-tail disruptions. Surprisingly, A to T mutations in the A-tail had little impact on the retrotransposition efficiency. However, interruptions by C or G had significantly larger impacts. Thus, the influence of interruptions in the A-tail is complex. Clearly additional attributes beyond the length of the longest run of As contribute to

TPRT priming efficiency. Table 2 shows that there are high levels of T residues within the A-tails early in *Alu* element evolution. This is somewhat surprising in that transversions are generally rarer than transitions. However, visual inspection of the Ya5 A-tails (Supplemental Table 1S) suggests that these T residues are less frequently the result of transversion mutations within the A-tail, and more from microsatellite-like amplifications from the A+T rich direct repeat region flanking the element. The *Alu*Sx elements contain higher levels of all base interruptions in their A-tails (Table 2), but the G and C mutations increase more proportionately, consistent with the accumulation of point mutations in the older A-tails. Thus, both the level of disruption and the higher incidence of G and C interruptions in the A-tails would jointly contribute to decrease activity from the Sx elements.

One of the most surprising influences on *Alu* activity levels is the distance between the A-tail at the 3' end of the *Alu* and the Pol III terminator located randomly downstream. We find that having the terminator very close to the A-tail allows maximum activity, while having as few as 15 random bases between the A-tail and the four T residues that cause the termination can result in as much as an order of magnitude decrease in activity. Thus, we estimate that >90% of new *Alu* inserts have relatively poor insertion capability even if they insert in a genomic region that allows them to transcribe actively. While this does not help to explain the relative activity differences observed between the Ya5 and Sx subfamilies, it does help lead to relatively few *Alus* having high levels of activity which is likely to contribute to the overall pattern of *Alu* evolution.

The most difficult aspect to assess *Alu* sequence variation is the influence of random mutations throughout the *Alu* element on the activity. Previous studies have shown that random mutations in the right monomer can have a modest effect on the RNA level of *Alu* elements (Alemán et al. 2000), that deletion of the right half decreases *Alu* activity by an order of magnitude (Dewannieux et al. 2003), and that deviation from *Alu* subfamily consensus sequences, particularly those >10% divergence, affects *Alu* retrotransposition efficiency (Bennett et al. 2008). In addition, previous studies altering the SRP9/14 binding motif in SINE RNAs showed a profound influence on activity (Sarowa et al. 1997; Dewannieux et al. 2003; Bennett et al. 2008). Some of the influence might include the specific bases that define the subfamilies themselves. However, subfamily diagnostic mutations have at most a two- to threefold influence on *Alu* activity (Bennett et al. 2008; B. Wagstaff and A. Roy-Engel, unpubl.). Our data assessed random mutations in the right half of the *Alu* RNA structure because of the complexity of dissecting the individual contribution of transcriptional and post-transcriptional influences that might be expected from mutating the left half of the *Alu* structure. Several of the random right halves selected from old, Sx, *Alu* subfamily members negatively impacted insertion efficiency while others did not. These influences were post-transcriptional as

Figure 5. The length of the 3' unique sequence drastically affects *Alu* retrotransposition capability. (A) Constructs with 30 homogenous As and variable 3' unique region lengths (0–126 bp) were evaluated by transient transfection of HeLa cells. The activity of these *Alu* elements under both exogenous (black bars) and endogenous (white bars) conditions of ORF2p is shown. The A30-0, an *Alu* with 30 homogenous As immediately followed by a terminator (TTTTT), was arbitrarily selected as the 100%; the asterisk (*) indicates significant difference from A30-0, $P < 0.01$ exogenous, $P < 0.03$ endogenous (Students paired *t*-test). (B) Northern blot analysis of poly(A) selected RNA extracts was performed from cells transfected with the A30-0 control and the variable A30 3' unique constructs. The unspliced (open arrowhead) and spliced (black arrow) neo-tagged *Alu* transcripts are indicated. The spliced *Alu* transcript from the variable length constructs were normalized to cyclophilin (C, loading control) and expressed relative to the A30-0 construct (designated as 1.00). The mean $\pm$ SD for the quantitation results for each construct are indicated below ($n = 3$). (C) Histogram of the length distribution of the 3' unique sequence of young and old *Alu* elements. The distribution of the length of 3' unique sequence (defined as the sequence between A-tail and the first four Ts in the 3' genomic flank) of a subset of randomly selected *AluSx* ($n = 289$) and *Ya5* ($n = 227$) families is shown as the frequency subdivided into bins of various sizes. (●) *Alu* elements containing a premature terminator within their internal dimeric sequence are included in this bin; *Sx* ($n = 25$), *Ya5* ($n = 1$).

we did not alter the promoter and saw only minimal variation in RNA levels.

We believe that it requires a combination of all of the factors described above to explain the relative inactivity of old *Alu* subfamilies and that these factors contribute differentially to silencing *Alu* elements at different stages of their evolution. For example,

previous studies suggested about a sixfold advantage in transcription per *Alu* copy on average between the old and new elements (Shaikh et al. 1997). If we combine this with a roughly threefold influence of subfamily mutations and a 10-fold influence of A-tail length and heterogeneity, we have the potential for 180-fold regulation. This is still ~ 20 -fold short of explaining the full regulation, but a large portion of this is likely to be explained by the influence of random mutations throughout the *Alu* element (Bennett et al. 2008). The activity may also not be a direct product of the factors measured here. There may be synergistic or more complicated interactions between different factors, such as A-tail length, and the level and distribution of heterogeneity.

Figure 8 presents a relative timeline on the implementation of these various levels of control. Thus, when a new *Alu* insert occurs, it is likely that its new surrounding DNA results in either a poor transcriptional environment (which includes epigenetic regulation) or a long 3' end that limits activity post-transcriptionally. Those *Alu* elements that are active in their new insertion site will then be subject to rapid shortening of their A-tail (Roy-Engel et al. 2002), which may also decrease activity. The A-tail accumulates variation relatively rapidly because of its microsatellite nature and therefore results in further inactivation of elements. Eventually, over many millions of years, the whole *Alu* element will accumulate sufficient mutations to either silence its promoter or alter its post-transcriptional activities to make it permanently silent.

Figure 6. Random right monomer mutations affect *Alu* retrotransposition capability. (A) Constructs of tagged *Alu* elements containing a randomly selected genomic *AluSx* right monomer with several mutations were evaluated by transient transfections in HeLa cells under exogenously supplied ORF2p conditions. The relative activity of these *Alu* elements is shown. The construct A30 that contains the consensus *AluYa5* right monomer was designated as 100. (B) A Northern blot analysis of the steady-state level of poly(A) selected RNA from the constructs in the same order as A is shown. The unspliced (open arrowhead) and spliced (black arrow) neo-tagged *Alu* transcripts are indicated. The spliced *Alu* transcript from the variable length constructs were normalized to cyclophilin (C, loading control) and expressed relative to the A30 construct (designated as 1.00). The mean $\pm$ SD for the quantitation results for each construct are indicated below ($n = 3$).

Cftr Alu insertion sequence

gtacctgtcaagactgcgctggttccaaatgagaatagaaatgatttttgcGGCCGGGCGCGGTGGCTCAC
 GCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCAGAGGTCAGGAGATCGAGACCA
 TCCCGGCTAAAACGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGGGCGTAGTGGC
 GGGCGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGAGG
 A AGCTTGCAGTGAGCCGAGATCCCGCCACTGCACTCCAGCCTGAGCGACAGAGCGAGACTCCGTCT
 CAAAAAAAAAAAAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAATAAAAAAAAAAatagaaat
gatttttgcatcttcttcattgctgttaccttccatttttaacaacaggtactatgaactcattaacttta
 gctaagca

Cftr insert parent locus**hg18 chr14:82539030-82539451**

tgctcttttaaaatcttaaatctatgggaatttacactgttaaagtgcacatcttaaaaaataatattttcGGC
 CGGGCGCGGTGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCAGGAG
 B GTCAGGAGATCGAGACCATCCCGGCTAAACGGTGAAACCCCGTCTCTACTAAAAATACAAAA
 ATTAGCCGGGCGTAGTGGCGGGCGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAAT
 GGCGTGAACCCGGGAGGAGAGCTTGCAGTGAGCCGAGATCCCGCCACTGCACTCCAGCCTGAG
 CGACAGAGCGAGACTCCGTCTCAAAAAAAAAAATAAAAAAAAAATAAataatattttctattt
 aatatataaatgcaggtgctgttagaca

A→T mutation mobilized
during retrotransposition

Pol-III terminator

Figure 7. Identification of the candidate source element for a disease-causing *Alu* insert. The sequence of the disease-causing *Alu* compared to the candidate source element found on chromosome 14 in the genome. The *Alu* sequences share 100% identity within the body of the element. (A) *Alu* insertion disrupting *Cftr* gene, exon 17b (Chen et al. 2008). Flanking sequence is lower case. Inserted *Alu* sequence is italicized. Bold text indicates the target site duplication formed during the retrotransposition process. The box outlines the thymine mutation that is inferred to have transferred to the progeny sequence during retrotransposition. Underlined portions within the direct repeat indicate the transcription terminator. (B) The parent locus of the *Cftr Alu* insertion. With the flanking sequence, *Alu*, target site duplication, thymine residue, and terminator labeled as in A.

There are still factors that we are unable to model in our studies with respect to individual loci, such as the influence of flanking sequences on Pol III transcription, or the possibility that very specific 3' unique sequences from a very limited number of *Alu* elements contribute in an unpredicted manner. Therefore, it is not possible to fully predict which *Alu* elements are active or, for that matter, how many. Our data demonstrate that the majority of new *Alu* insertions are probably not very active upon insertion and this may help explain the low numbers active that could result in the pattern of evolution observed. In addition, because *Alu* elements contribute to genetic instability and disease, it is possible that there is genetic selection against the most active elements. This leaves the possibility that an *Alu* element that inserts into a favorable genomic environment (both for transcription and 3' unique region) may undergo negative selection. This would lead to either its selective elimination from the population or rapid changes, such as A-tail length or heterogeneity that eliminates its activity. Thus, even though certain characteristics between old and young *Alu* subfamily members may look similar, it may be that all of the features necessary for activity are present only among a small group of the very youngest elements, those for which selection has not had sufficient time to remove from the population.

The finding that the most likely source element for a recent *Alu* insertion in the *Cftr* locus (Chen et al. 2008) was predicted based on its sequence similarity and shared T in the A-rich region (Fig. 7) also conforms to our rules of active elements having short 3' ends and long, relatively perfect A-tails. This represents the first identification of a likely source element for a disease-causing *Alu* element and illustrates how our increasing understanding of the

factors influencing *Alu* element activity can help us predict the potential strength of individual *Alu* elements and potentially predict likely source elements for other *Alu* insertions causing disease.

Figure 8. Time frame of events influencing *Alu* element activity. (1) De novo *Alu* insertion acquiring new 5' transcription regulators and 3' unique sequence which dramatically affect future retrotransposition efficiency. In addition, epigenetic changes will impact transcriptional capability of the *Alu* insert. (2) *Alu* A-tail length shortening occurs rapidly after insertion to squelch future activity. (3) The quick introduction of heterogeneity in the A-tail through microsatellite expansion causing an additional reduction in retrotransposition efficiency. (4) Slower and random accumulation of random mutations throughout the element including mutations to the A and B box reducing *Alu* transcription efficiency, mutations in the A-tail increasing heterogeneity, and mutations throughout the left and right monomers reducing overall identity with a consensus sequence possibly affecting RNA stability and structure.

In a number of our studies, the level of expression of ORF2p driving the tagged *Alu* insertion (Wallace et al. 2008) appeared to have a significant influence. Most studies using this *Alu* retrotransposition assay make use of either overexpression of an L1 or simply of ORF2 from L1. We were able to obtain measurable levels of *Alu* activity in HeLa cells from the endogenous expression of L1 in these cells. Although our data did not see a significant influence on *Alu* activity due to A-tail length (Fig. 2) based on ORF2p expression levels, we saw consistently stronger influences from A-tail interruptions, the length of 3' unique regions, as well as from random mutations in the right half, when we used only endogenous levels of L1 to drive the *Alu*. We envision that at high levels of ORF2p expression even relatively poor *Alu* substrates can form active insertion complexes. However, at lower ORF2p levels, other cellular RNAs, or even endogenous *Alus*, compete for the ORF2p and it is less available for the less favorable *Alu* elements. Even HeLa cells may have higher levels of L1 expression than typical normal cells (Perepelitsa-Belancio and Deininger 2003; Belancio et al. 2006), and therefore it is possible that our measurements of the various factors that influence *Alu* activity are underestimates of the potential influence each has in normal cells.

Methods

Plasmid constructs

All of the constructs used in this study are based on the *AluYa5-neo^{TET}* retrotransposition cassette provided by T. Heidmann (Dewannieux et al. 2003). Modifications (shown in Fig. 1B) via the Quick Change mutagenesis kit (Stratagene) were made to introduce a MluI site between the SV40 promoter in the reverse orientation and the A-tail of the *Alu* (see Supplemental Table 3S for primers), and the modified retrotransposition cassette was moved into pZero-Zeo (Invitrogen). Complementary oligonucleotides were synthesized (IDT) with the appropriate ends to introduce the desired 3' sequence (Supplemental Table 3S) into the MluI-EcoRI site to generate the different A-tail length and heterogeneity constructs.

The 3' unique region constructs were built into the modified 30 pure A pZero vector from the heterogeneity study. Oligonucleotides were synthesized that contained a 30-base A-tail to introduce an NdeI site after the 30 As (Fig. 1B; Supplemental Table 3S). These oligonucleotides contained overlaps that allowed them to be cloned into the digested pZero backbone between the MluI site and the EcoRI site. This vector, pZero^{7SL}*AluNdeIneo^{TET}*, was confirmed by DNA sequencing. The 3'-15, 3'-38, and 3'-45 constructs were built by annealing NdeI and EcoRI containing oligonucleotides and inserting them into pZero. The 3'-70 and -126 unique end sequences were isolated from HeLa genomic DNA by specific PCR amplification of the selected genomic locations. The primers were designed so that they would have NdeI and EcoRI overhangs so they could be inserted into the compatible locations of the pZero-NdeI vector (Supplemental Table 3S).

The random right monomer constructs were generated in the *Alu* retrotransposition cassette within the Topo-TA 2.1 vector that had the kanamycin resistance cassette removed by digestion with MscI and RsrII followed by Mung Bean Nuclease treatment and religated with T4 DNA ligase. A SpeI site was introduced using site-directed mutagenesis into the middle A-rich region of the *Alu* making p^{7SL}*AluSpeIneo^{TET}*. Randomly selected *Alu* right monomers from the genome, isolated by PCR (Supplemental Table 3S), were cloned into this vector using the SpeI and AatII sites found at the 3' end of the *Alu* element (Fig. 1B). All constructs were confirmed by sequencing (TGen) to ensure proper subcloning. Plasmids were isolated and purified by double-banding in CsCl.

Transfection

500,000 or 100,000 HeLa cells were seeded onto a 75-cm² cell culture flask the day before the transfection to evaluate *Alu* retrotransposition driven by endogenous L1 or by ORF2 or L1 expression plasmids, respectively. Transfections were carried out using Lipofectamine and Plus Reagents according to the manufacturer's protocol (Invitrogen). For L1 or ORF2 complemented retrotransposition assays, 2 µg of *Alu*-containing plasmid were transfected with 1 µg of the appropriate driver plasmid per flask. For assays using endogenous L1 expression, only 2 µg of *Alu* retrotransposition plasmid were added to the transfection solution. The transfection solution was left on the cells for 3 h with DMEM (GIBCO) without serum; after this incubation period, the medium was removed and MEM (GIBCO) supplemented with 10% FBS (Atlanta Biologicals), and 1× sodium pyruvate, 1× non-essential amino acids, and Pen/Strep (GIBCO) were added to these cells. After 24 h, G418 selection medium with 400 µg/mL Geneticin (Invitrogen) was added and the cells were grown for 2 wk. Medium was changed on the cells every three days, and after 2 wk, colonies were fixed and stained with crystal violet prior to automated colony counting (Colcount, Oxford Optronics) or manual counting. Each experiment contained three flasks for each construct, and each experiment was repeated three times to obtain the relative number of colonies compared to an *Alu* with a 30-base pure A-tail.

Data mining

In order to assess A-tail length and heterogeneity of genomic *Alus*, 276 elements from the *AluSx* and 206 elements from the *AluYa5* families were randomly sampled from the RepeatMasker annotation of build 36.1 (hg18) of the human genome and extracted, along with 5000 bp of flanking sequence, using in-house Perl scripts. The 3' Flank studies came from this same data set but included 289 *AluSx* elements from chromosomes 1, 2, and 3 plus the 227 total *AluYa5* elements. The boundaries of the A-tail were defined by first identifying the target site duplications flanking the *Alu* insertion, then subsequently defining the end of the tail as the first non-A base in the second (3') TSD site (Roy-Engel et al. 2002). The initiation of the A-tail was defined by the first A-nucleotide subsequent to the conserved 3' *Alu* consensus motif. Nucleotide composition was calculated using the previously described boundaries. The length of uninterrupted As in the A-tail was determined by counting from the initiation of the tail until the first non-A nucleotide. GC content of the A-tail, and the distance after the A-tail and before the genomic terminator were also assessed.

Northern blot analyses

RNA extraction and poly(A) selection were performed 48 h post-transfection as previously described (Perepelitsa-Belancio and Deininger 2003). Briefly, total RNA was extracted from two 75-cm² cell culture flasks transfected with the *Alu* construct of interest using the TRIzol Reagent (Invitrogen) following the protocol supplied by the manufacturer. Poly(A) selection was performed using the PolyAtract mRNA isolation system III (Promega) following the manufacturer's protocol. The poly(A) RNA was separated by electrophoresis in a 2% agarose-formaldehyde gel and transferred to a Hybond-N nylon membrane (Amersham Biosciences). The RNA was cross-linked to the membrane using a UV-light (GS Gene linker, BioRad) and pre-hybridized in 5× SSC, 5× Denhardt's, 1% SDS, and 100 µg/mL herring sperm DNA for at least 6 h at 60°C. A riboprobe complementary to the neomycin gene was used. A DNA template was amplified by PCR using the following primers T7neo(-): 5'-TAATACGACTCACTATAAGGACG

AGGCAGCG-3' and Neo northern(+): 5'-GAAGAACTCGTCAAG AAGG-3'. The isolated PCR product was used as a DNA template to generate a ^{32}P -UTP (MP Biomedicals) labeled single strand-specific RNA probe using the MAXIscript T7 kit (Ambion) following the manufacturer's recommended protocol. We generated a riboprobe for cyclophilin (Ambion) to use as loading control. The radio-labeled probe was purified by filtration through a NucAway Spin column (Ambion). Hybridization with the probe (final concentration of $4\text{--}12 \times 10^6$ cpm/mL) was carried out overnight in the hybridization solution consisting of 30% formamide, $1\times$ Denhardt's solution, 1% SDS, 1 M NaCl, 100 $\mu\text{g/mL}$ salmon sperm DNA, 100 $\mu\text{g/mL}$ yeast tRNA at 60°C . The membranes were washed twice for 15 min with a high stringency wash buffer ($0.1\times$ SSC, 0.1% SDS) at 60°C . The results of the Northern blot assays were evaluated using a Typhoon PhosphorImager (Amersham Biosciences) and quantitated with the ImageQuant software.

Real-time reverse transcriptase PCR

Total RNA extraction was performed 24 h post-transfection from 75-cm^2 cell culture flasks transfected with the A-tail heterogeneity constructs as described above. cDNA was generated from the extracted RNA samples using a commercially available reverse transcription system (Promega) and evaluated by real-time PCR using Platinum SYBR Green Kit (Invitrogen) in a Bio-Rad IQ5 Real-Time PCR Detection System following the manufacturers' protocols. The following primers were used: neomycin selection cassette of the *Alu* construct: 5'-CCTCGGCCTCTGAGCTATTC-3' and 5'-AGTCCCTTCCCGCTTCAGTGACAAC-3', and GAPDH: 5'-GAAATCCCATCACCATCTTCCAGG-3' and 5'-GAGCCCCAGCCTTCTCATG-3' (West et al. 2004). Quantitation of the RNA from each heterogeneity construct was performed relative to the A30 control.

Acknowledgments

This publication was made possible by Grants Number P2ORR020152 (P.L.D., A.M.R.-E.), R01GM45668 and NSF EPSCOR grant (P.L.D.) and R01GM079709A (A.M.R.-E.) from the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRP or NIH. Competitive Advantage Funds (2006) from the Louisiana Cancer Research Consortium (LCRC) were also awarded to A.M.R.-E.

References

Alemán, C., Roy-Engel, A.M., Shaikh, T.H., and Deininger, P.L. 2000. Cis-acting influences on *Alu* RNA levels. *Nucleic Acids Res.* **28**: 4755–4761.

Arcot, S.S., Wang, Z., Weber, J.L., Deininger, P.L., and Batzer, M.A. 1995. *Alu* repeats: A source for the genesis of primate microsatellites. *Genomics* **29**: 136–144.

Batzer, M.A. and Deininger, P.L. 2002. *Alu* repeats and human genomic diversity. *Nat. Rev. Genet.* **3**: 370–379.

Batzer, M.A., Schmid, C.W., and Deininger, P.L. 1993. Evolutionary analyses of repetitive DNA sequences. *Methods Enzymol.* **224**: 213–232.

Belancio, V.P., Hedges, D.J., and Deininger, P. 2006. LINE-1 RNA splicing and influences on mammalian gene expression. *Nucleic Acids Res.* **34**: 1512–1521.

Belancio, V.P., Hedges, D.J., and Deininger, P. 2008. Mammalian non-LTR retrotransposons: For better or worse, in sickness and in health. *Genome Res.* **18**: 343–358.

Bennett, E.A., Keller, H., Mills, R.E., Schmidt, S., Moran, J.V., Weichenrieder, O., and Devine, S.E. 2008. Active *Alu* retrotransposons in the human genome. *Genome Res.* **18**: 1875–1883.

Boeke, J.D. 1997. LINEs and *Alus*—The polyA connection. *Nat. Genet.* **16**: 6–7.

Chen, J.M., Masson, E., Macek Jr., M., Raguene, O., Piskackova, T., Fercot, B., Fila, L., Cooper, D.N., Audrezet, M.P., and Ferec, C. 2008. Detection of two *Alu* insertions in the *Cfr* gene. *J. Cyst. Fibros.* **7**: 37–43.

Chesnokov, I. and Schmid, C.W. 1996. Flanking sequences of an *Alu* source stimulate transcription in vitro by interacting with sequence-specific transcription factors. *J. Mol. Evol.* **42**: 30–36.

Chu, W.M., Liu, W.M., and Schmid, C.W. 1995. RNA polymerase III promoter and terminator elements affect *Alu* RNA expression. *Nucleic Acids Res.* **23**: 1750–1757.

Cordaux, R., Hedges, D.J., Herke, S.W., and Batzer, M.A. 2006. Estimating the retrotransposition rate of human *Alu* elements. *Gene*. **373**: 134–137.

Deininger, P.L. and Batzer, M.A. 1995. SINE master genes and population biology. *The impact of short interspersed elements (SINEs) on the host genome* (ed. R.J. Maraia), pp. 43–60. RG Landes, Georgetown, TX.

Deininger, P.L. and Batzer, M.A. 1999. *Alu* repeats and human disease. *Mol. Genet. Metab.* **67**: 183–193.

Dewannieux, M. and Heidmann, T. 2005. Role of poly(A) tail length in *Alu* retrotransposition. *Genomics* **86**: 378–381.

Dewannieux, M., Esnault, C., and Heidmann, T. 2003. LINE-mediated retrotransposition of marked *Alu* sequences. *Nat. Genet.* **35**: 41–48.

Englander, E.W., Wolffe, A.P., and Howard, B.H. 1993. Nucleosome interactions with a human *Alu* element. Transcriptional repression and effects of template methylation. *J. Biol. Chem.* **268**: 19565–19573.

Gilbert, N., Lutz, S., Morrish, T.A., and Moran, J.V. 2005. Multiple fates of L1 retrotransposition intermediates in cultured human cells. *Mol. Cell. Biol.* **25**: 7780–7795.

Han, K., Xing, J., Wang, H., Hedges, D.J., Garber, R.K., Cordaux, R., and Batzer, M.A. 2005. Under the genomic radar: The stealth model of *Alu* amplification. *Genome Res.* **15**: 655–664.

Hedges, D.J., Callinan, P.A., Cordaux, R., Xing, J., Barnes, E., and Batzer, M.A. 2004. Differential *Alu* mobilization and polymorphism among the human and chimpanzee lineages. *Genome Res.* **14**: 1068–1075.

Jurka, J. 1997. Sequence patterns indicate an enzymatic involvement in integration of mammalian retrotransposons. *Proc. Natl. Acad. Sci.* **94**: 1872–1877.

Kajikawa, M. and Okada, N. 2002. LINEs mobilize SINEs in the eel through a shared 3' sequence. *Cell* **111**: 433–444.

Kazazian, Jr., H.H. 2004. Mobile elements: Drivers of genome evolution. *Science* **303**: 1626–1632.

Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W. et al. 2001. Initial sequencing and analysis of the human genome. *Nature* **409**: 860–921.

Liu, W.M. and Schmid, C.W. 1993. Proposed roles for DNA methylation in *Alu* transcriptional repression and mutational inactivation. *Nucleic Acids Res.* **21**: 1351–1359.

Liu, W.M., Maraia, R.J., Rubin, C.M., and Schmid, C.W. 1994. *Alu* transcripts: Cytoplasmic localisation and regulation by DNA methylation. *Nucleic Acids Res.* **22**: 1087–1095.

Ludwig, A., Rozhdestvensky, T.S., Kuryshv, V.Y., Schmitz, J., and Brosius, J. 2005. An unusual primate locus that attracted two independent *Alu* insertions and facilitates their transcription. *J. Mol. Biol.* **350**: 200–214.

Maraia, R.J., Driscoll, C.T., Bilyeu, T., Hsu, K., and Darlington, G.J. 1993. Multiple dispersed loci produce small cytoplasmic *Alu* RNA. *Mol. Cell. Biol.* **13**: 4233–4241.

Mills, R.E., Bennett, E.A., Iskow, R.C., and Devine, S.E. 2007. Which transposable elements are active in the human genome? *Trends Genet.* **23**: 183–191.

Murphy, D., Brickell, P.M., Latchman, D.S., Willison, K., and Rigby, P.W.J. 1983. Transcripts regulated during normal embryonic development and oncogenic transformation share a repetitive element. *Cell* **35**: 865–871.

Odom, G.L., Robichaux, J.L., and Deininger, P.L. 2004. Predicting mammalian SINE subfamily activity from A-tail length. *Mol. Biol. Evol.* **21**: 2140–2148.

Ostertag, E.M., Goodier, J.L., Zhang, Y., and Kazazian, Jr., H.H. 2003. SVA elements are nonautonomous retrotransposons that cause disease in humans. *Am. J. Hum. Genet.* **73**: 1444–1451.

Perepelitsa-Belancio, V. and Deininger, P.L. 2003. RNA truncation by premature polyadenylation attenuates human mobile element activity. *Nat. Genet.* **35**: 363–366.

Roy, A.M., West, N.C., Rao, A., Adhikari, P., Alemán, C., Barnes, A.P., and Deininger, P.L. 2000. Upstream flanking sequences and transcription of SINEs. *J. Mol. Biol.* **302**: 17–25.

Roy-Engel, A.M., Salem, A.H., Oyeniran, O.O., Deininger, L., Hedges, D.J., Kilroy, G.E., Batzer, M.A., and Deininger, P.L. 2002. Active *Alu* element "A-Tails": Size does matter. *Genome Res.* **12**: 1333–1344.

Sarrowa, J., Chang, D.Y., and Maraia, R.J. 1997. The decline in human *Alu* retroposition was accompanied by an asymmetric decrease in SRP9/14 binding to dimeric *Alu* RNA and increased expression of small cytoplasmic *Alu* RNA. *Mol. Cell. Biol.* **17**: 1144–1151.

Sassaman, D.M., Dombroski, B.A., Moran, J.V., Kimberland, M.L., Naas, T.P., DeBerardinis, R.J., Gabriel, A., Swergold, G.D., and Kazazian, Jr., H.H. 1997. Many human L1 elements are capable of retrotransposition. *Nat. Genet.* **16**: 37–43.

- Shaikh, T.H., Roy, A.M., Kim, J., Batzer, M.A., and Deininger, P.L. 1997. cDNAs derived from primary and small cytoplasmic Alu (scAlu) transcripts. *J. Mol. Biol.* **271**: 222–234.
- Shen, M.R., Batzer, M.A., and Deininger, P.L. 1991. Evolution of the master Alu gene(s). *J. Mol. Evol.* **33**: 311–320.
- Sinnett, D., Richer, C., Deragon, J.M., and Labuda, D. 1991. Alu RNA secondary structure consists of two independent 7 SL RNA-like folding units. *J. Biol. Chem.* **266**: 8675–8678.
- Sinnett, D., Richer, C., Deragon, J.M., and Labuda, D. 1992. Alu RNA transcripts in human embryonal carcinoma cells. Model of post-transcriptional selection of master sequences. *J. Mol. Biol.* **226**: 689–706.
- Ullu, E. and Tschudi, C. 1984. *Alu* sequences are processed 7SL RNA genes. *Nature* **312**: 171–172.
- Wallace, N., Wagstaff, B.J., Deininger, P.L., and Roy-Engel, A.M. 2008. LINE-1 ORF1 protein enhances Alu SINE retrotransposition. *Gene* **419**: 1–6.
- Wang, J., Song, L., Gonder, M.K., Azrak, S., Ray, D.A., Batzer, M.A., Tishkoff, S.A., and Liang, P. 2006. Whole genome computational comparative genomics: A fruitful approach for ascertaining *Alu* insertion polymorphisms. *Gene* **365**: 11–20.
- Wei, W., Gilbert, N., Ooi, S.L., Lawler, J.F., Ostertag, E.M., Kazazian, H.H., Boeke, J.D., and Moran, J.V. 2001. Human L1 retrotransposition: *Cis* preference versus *trans* complementation. *Mol. Cell. Biol.* **21**: 1429–1439.
- West, A.B., Kapatos, G., O'Farrell, C., Gonzalez-de-Chavez, F., Chiu, K., Farrer, M.J., and Maidment, N.T. 2004. N-myc regulates parkin expression. *J. Biol. Chem.* **279**: 28896–28902.

Received December 2, 2008; accepted in revised form February 9, 2009.

Diverse *cis* factors controlling *Alu* retrotransposition: What causes *Alu* elements to die?

Matthew S. Comeaux, Astrid M. Roy-Engel, Dale J. Hedges, et al.

Genome Res. 2009 19: 545-555 originally published online March 9, 2009

Access the most recent version at doi:[10.1101/gr.089789.108](https://doi.org/10.1101/gr.089789.108)

Supplemental Material <http://genome.cshlp.org/content/suppl/2009/03/20/gr.089789.108.DC1>

References This article cites 45 articles, 14 of which can be accessed free at:
<http://genome.cshlp.org/content/19/4/545.full.html#ref-list-1>

Open Access Freely available online through the *Genome Research* Open Access option.

License Freely available online through the Genome Research Open Access option.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Affordable, Accurate
Sequencing.

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>